COMMUNIQUÉS West-GlobeNewswire

BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe
03/04/2018
April 3, 2018 Announcement no. 7 BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe The European Patent Office has published intention to grant BioPorto’s patent no. EP3208616. The patent [...]
Solon Eiendom ASA : Sales in Q1 2018
03/04/2018
Oslo, April 3, 2018 - Solon Eiendom sold 124 homes with a total sales value of NOK 819 million during the first quarter of 2018 compared to 58 homes with a total sales value of NOK 407 million in the first quarter of [...]
Publication of Biohit Oyj Annual Report 2017
03/04/2018
Biohit Oyj Annual Financial Report April 3, 2018 at 9:30 am local time (EET) Biohit Oyj’s Annual Report 2017 is published today in PDF format. The annual report contains financial statements for 2017, the Report of the [...]
Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program
03/04/2018
Press Release 3 April 2018 Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program Immunicum AB (publ; IMMU.ST) provided today an update on planned, ongoing and previously completed clinical [...]
Shire plc : Rule 2.9 Announcement
03/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 April 2018 Shire [...]
genedrive to premier its Genedrive® Hepatitis C test in Asia Pacific
03/04/2018
3 April 2018 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit to be presented at MEDLAB Asia Pacific Exhibition & Congress genedrive plc (AIM: GDR), the near patient molecular diagnostics company, [...]
Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update
03/04/2018
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the initiation of a rolling [...]
DBV Technologies to Attend the 11th Kempen Life Sciences Conference
03/04/2018
Montrouge, April 3, 2018 DBV Technologies to Attend the 11 th Kempen Life Sciences Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief [...]
DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen
03/04/2018
Montrouge, France, le 3 avril, 2018 (7H30 CEST) DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]
Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
03/04/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma Paris and Tarrytown, NY - April 3, 2018 - The European Medicines [...]
Sanofi : L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé
03/04/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner le cemiplimab comme traitement potentiel du carcinome épidermoïde cutané au stade avancé Paris et Tarrytown (New York) - Le 3 avril [...]
Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
03/04/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review Dupixent ® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma Paris and Tarrytown, NY - April 3, 2018 - The [...]
Sanofi : L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé
03/04/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) L'EMA va examiner Dupixent® (dupilumab) dans le traitement potentiel de l'asthme modéré à sévère inadéquatement contrôlé Paris et Tarrytown (New York [...]
Fagron strengthens strategic position in USA through highly complementary acquisition of Humco
03/04/2018
Nazareth (Belgium)/Rotterdam (The Netherlands) 1 , 3 April 2018 Regulated information - Inside information Fagron strengthens strategic position in USA through highly complementary acquisition of Humco Fagron announces [...]
argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
03/04/2018
Company to host workshop and webcast on April 24, 2018 at 1:00 p.m. PT April 3, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a [...]
Probiodrug reports full year 2017 financial results
03/04/2018
Probiodrug reports full year 2017 financial results PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients - data presented at CTAD, Boston, November 2017 PQ912 Phase [...]
Veloxis Appoints Morten Marott as Chief Financial Officer
03/04/2018
Company Release no. 08/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 April 2018 Veloxis Appoints Morten Marott as Chief Financial Officer Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten [...]
Operational Update
03/04/2018
First two patients of the additional cohort of the Phase I, TACTI-mel trial have commenced treatment; data to be reported mid-2018 AIPAC trial: 33 out of a planned 34 clinical sites now active with full recruitment [...]
REVA Initiates Commercial Distribution Partnership in Turkey
03/04/2018
SAN DIEGO, April 02, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced that it will initiate commercial [...]

Pages